- Poster presentation
- Open Access
Generation and utilization of polyfunctional anti-tumor CD4+ T cells
Journal for ImmunoTherapy of Cancer volume 3, Article number: P63 (2015)
There is accumulating evidence that polyfunctional T cells, effector T cells capable of simultaneously producing multiple pro-inflammatory cytokines, are more efficacious in controlling infection and cancer. However, how polyfunctional CD4+ effector cells are induced is not mechanistically understood.
In this study we established that IL7 can promote the acquisition of polyfunctionality in naïve CD4+ T cells upon antigenic stimulation in vitro. In particular, IL7-conditioned polyfunctional CD4+ T cells can concomitantly express IFN-γ, TNF-α, IL-2 and granzyme B, with a separate IL4-producing population. We demonstrated that IL7 signaling resulted in increased histone acetylation in the promoters of effector molecules including IFN-γ, TNF-Αalpha, IL-2 and granzyme B, but not in Foxp3 and PD1, suggesting a selective enhancement in chromatin accessibility.
Mechanistically, STAT5 is required for IL7-driven polyfunctionality as expression of constitutive active STAT5 mutant in CD4+ T cells conferred polyfunctionality to CD4+ T cells even in the absence of IL7, whereas expression of dominant negative STAT5 mutant abolished IL7-driven polyfunctionality. Surprisingly, fully armed polyfunctional CD4+ T cells did not exhibit potent anti-tumor effect when adoptively transferred into mice with established B cell lymphoma, suggesting the dominance of immune suppression in the tumor microenvironment. Durable curative anti-tumor effect can be achieved by providing TriVax, a vaccine consisting of peptide, poly-IC adjuvant and OX40 antibody, following polyfunctional CD4+ T cell transfer.
Our results provide novel insights into the generation of polyfunctional CD4+ effector cells and their potential usage in cancer immunotherapy.
About this article
Cite this article
Zhou, G., Ding, Z. Generation and utilization of polyfunctional anti-tumor CD4+ T cells. j. immunotherapy cancer 3, P63 (2015). https://doi.org/10.1186/2051-1426-3-S2-P63
- Tumor Microenvironment
- Effector Cell
- STAT5 Mutant
- Histone Acetylation
- Cancer Immunotherapy